Cargando…

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Several fibroblast growth factor receptor (FGFR) inhibitors are approved or in clinical development for the treatment of FGFR-driven urothelial cancer, and molecular mechanisms of resistance leading to patient relapses have not been fully explored. We identified 21 patients with FGFR-driven urotheli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Facchinetti, Francesco, Hollebecque, Antoine, Braye, Floriane, Vasseur, Damien, Pradat, Yoann, Bahleda, Rastislav, Pobel, Cédric, Bigot, Ludovic, Déas, Olivier, Florez Arango, Juan David, Guaitoli, Giorgia, Mizuta, Hayato, Combarel, David, Tselikas, Lambros, Michiels, Stefan, Nikolaev, Sergey I., Scoazec, Jean-Yves, Ponce-Aix, Santiago, Besse, Benjamin, Olaussen, Ken A., Loriot, Yohann, Friboulet, Luc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481128/ https://www.ncbi.nlm.nih.gov/pubmed/37377403 http://dx.doi.org/10.1158/2159-8290.CD-22-1441

Ejemplares similares

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
por: Recondo, Gonzalo, et al.
Publicado: (2020)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
por: Enrico, Diego, et al.
Publicado: (2020)

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
por: Furugaki, Koh, et al.
Publicado: (2023)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
por: Guaitoli, Giorgia, et al.
Publicado: (2021)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2018)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study
por: Nan, Hongmei, et al.
Publicado: (2009)

Role of Postnatal Expression of Fgfr1 and Fgfr2 in Testicular Germ Cells on Spermatogenesis and Fertility in Mice
por: Li, Shengqiang, et al.
Publicado: (2014)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province
por: Jiang, Yongdong, et al.
Publicado: (2015)

Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3
por: Kawane, Tetsuya, et al.
Publicado: (2018)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
por: Lu, Hengyu, et al.
Publicado: (2020)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
por: Sridharan, Vishwajith, et al.
Publicado: (2022)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
por: Wang, Zechen, et al.
Publicado: (2023)

FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
por: Elbauomy Elsheikh, Somaia, et al.
Publicado: (2007)

FGFR2 amplification in colorectal adenocarcinoma
por: Carter, Jamal H., et al.
Publicado: (2017)

Fetal microtia and FGFR2 polymorphism
por: Zhao, Ruilian, et al.
Publicado: (2019)

Role of FGFR3 in Urothelial Carcinoma
por: Akanksha, Malik, et al.
Publicado: (2019)

FGF/FGFR signaling in health and disease
por: Xie, Yangli, et al.
Publicado: (2020)

Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
por: Wu, Daichao, et al.
Publicado: (2016)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance
por: Kikuchi, Aya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3d1l34rdnhhqi1m1f0doge8c69